Table 1 Demographic characteristics of the study samples
From: Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
ranibizumab (Lucentis®) | bevacizumab (Avastin®) | |
|---|---|---|
Sex (No. of patient) | ||
Female | 9 (37.5%) | 11 (50.0%) |
Male | 15 (62.5%) | 11 (50.0%) |
Total | 24 | 22 |
Age, years (No. of patients) | ||
50–59 | 3 (12.5%) | 2 (9.1%) |
60–69 | 4 (16.7%) | 7 (31.8%) |
70–79 | 2 (8.3%) | 6 (27.3%) |
80+ | 15 (62.5%) | 7 (31.8%) |
Mean [Min;Max] | 78.7 [51.0;93.8] | 73.8 [58.7;88.8] |
Causes of death (No. of patients) | ||
Cancer | 5 (20.8%) | 5 (22.7%) |
Cerebrovascular disease | 7 (29.2%) | 4 (18.2%) |
Coronary heart disease | 8 (33.3%) | 11 (50.0%) |
Respiratory diseases | 4 (16.7%) | 2 (9.1%) |
Culture conditions | ||
culture time [d] (Mean [Range]) | 23.0 [11.0;42.0] | 28.0 [10.0;43.0] |
death-to-enucleation-time [h] (Mean [Range]) | 26.7 [6.3;49.4] | 29.6 [10.9;54.4] |
death-to-culture-time [h] (Mean [Range]) | 52.2 [10.2;96.9] | 61.7 [20.0;138.5] |
Reasons for Unsuitability of Donor Corneas | ||
Endothelial Cell Count < 2000 Cells/mm2 | 4 (16.7%) | 5 (22.7%) |
Positive Conjunctival Swab | 6 (25.0%) | 11 (50.0%) |
Positive or Unclear Serology | 12 (50.0%) | 5 (22.7%) |
Contamination of Fellow Eye | 2 (8.3%) | 1 (4.6%) |